StreetInsider.com News Articles

Form 144 ALNYLAM PHARMACEUTICALS, Filed by: SUPRAN BRYAN

Fri, 02 Oct 2026 15:46:00 -0400

si-local-file:///var/storage/secattach/20261002/27141856.html

Alnylam Pharmaceuticals (ALNY) PT Lowered to $369 at JPMorgan

Wed, 30 Sep 2026 09:09:24 -0400

JPMorgan analyst Jessica Fye lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $369.00 (from $375.00) while maintaining a Overweight rating.

Alnylam Pharmaceuticals (ALNY) Reiterated at Neutral by Cantor Fitzgerald Amid Exciting Pipeline Inbounds

Wed, 30 Sep 2026 06:58:15 -0400

Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating and $325.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented, "We've been getting a lot more inbounds on ALNY's initial ALN-HTT02 Huntington's disease (HD) data coming October 23rd at EHDN (followed by a dedicated RNAi Roundtable on October 26th). So, we did some digging. Here's why we think this one matters. Investors have been looking for a reason to get more excited about ALNY's pipeline again - and Huntington's is a big/buzzy enough opportunity to potentially do it. QURE (OW, covered by K. Kluska) has also made the HTT-lowering story

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Tue, 29 Sep 2026 09:00:00 -0400

– Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM Diagnosis –

– ‘Play by Play’ Uses Sports to Highlight the Strength of Earlier Diagnosis, TTR Silencing with AMVUTTRA, and Navigating ATTR-CM through Teamwork –

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Tue, 29 Sep 2026 09:00:00 -0400

– Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM Diagnosis –

– ‘Play by Play’ Uses Sports to Highlight the Strength of Earlier Diagnosis, TTR Silencing with AMVUTTRA, and Navigating ATTR-CM through Teamwork –

Form 4 ALNYLAM PHARMACEUTICALS, For: Sep 19 Filed by: Greenstreet Yvonne

Tue, 22 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260922/27091096.html

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Mon, 21 Sep 2026 07:29:23 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $455.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "The Phase 3 bar is now explicit — we reiterate our Buy rating and $455 price target on ALNY. On September 17, Alnylam hosted its 10th RNA interference (RNAi) Roundtable, dedicated to zilebesiran, an investigational RNAi therapeutic targeting angiotensinogen (AGT) in development with Roche (ROG.SW; not rated) for hypertension in patients with established cardiovascular (CV) disease or at high CV risk (link to webcast and deck). The most incremental disclosure was quantitative: management said a 15% to 20% reduction in

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Mon, 21 Sep 2026 07:29:23 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $455.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

Truist Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Mon, 21 Sep 2026 06:56:52 -0400

Truist Securities analyst Danielle Brill reiterated a Buy rating and $315.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "Alnylam hosted a webcast highlighting the opportunity for zilebesiran, its siRNA targeting angiotensinogen (AGT) for hypertension. Recall that the Ph 3 ZENITH CVOT is ongoing, with topline data expected in 2030. Bottom Line: ALNY reiterated its view that sustained blood pressure (BP) control and improved adherence could translate into meaningful reductions in CV risk. While we agree that infrequent dosing may address compliance challenges associated with current antihypertensive therapies, we remain cautious on the safety profile and continue to question

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Wed, 02 Sep 2026 06:54:58 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $455.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "On August 28, primary results for Ionis Pharmaceuticals' and AstraZeneca's antisense oligonucleotide (ASO) eplontersen (WAINUA) were presented in a Hot Line session at the European Society of Cardiology (ESC) Congress 2026, held August 28-31 in Munich, and published simultaneously in the New England Journal of Medicine; a prespecified stabilizer-subgroup analysis followed on August 30 and was published in Nature Medicine. The composite of cardiovascular (CV) death and recurrent CV events through Week 140 produced 381 events in 210 of 715

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'